| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/MUS.21808 |
| P698 | PubMed publication ID | 21038378 |
| P50 | author | Craig M. McDonald | Q51125801 |
| Alina Nicorici | Q84476675 | ||
| P2093 | author name string | Jay J Han | |
| R Ted Abresch | |||
| Leone Atkinson | |||
| Erik K Henricson | |||
| Langdon L Miller | |||
| Allen Reha | |||
| Gary L Elfring | |||
| P2860 | cites work | ATS Statement | Q34136219 |
| Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. | Q36005563 | ||
| P433 | issue | 6 | |
| P921 | main subject | muscular dystrophy | Q1137767 |
| P304 | page(s) | 966-974 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Muscle and Nerve | Q15764281 |
| P1476 | title | The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations | |
| P478 | volume | 42 |
| Q48505622 | A Simple and Low-cost Assay for Measuring Ambulation in Mouse Models of Muscular Dystrophy. |
| Q38019990 | A critical review of functional assessment tools for upper limbs in Duchenne muscular dystrophy. |
| Q36422465 | Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy. |
| Q35519892 | Age-related longitudinal changes in metabolic energy expenditure during walking in boys with Duchenne muscular dystrophy. |
| Q47607031 | An Overview of Recent Therapeutics Advances for Duchenne Muscular Dystrophy |
| Q28084979 | Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy |
| Q34561960 | Ataluren treatment of patients with nonsense mutation dystrophinopathy |
| Q93073995 | Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy |
| Q90042696 | Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study |
| Q45752246 | Correlation of knee strength to functional outcomes in Becker muscular dystrophy |
| Q57493593 | Cross-section and feasibility study on the non-invasive evaluation of muscle hemodynamic responses in Duchenne muscular dystrophy by using a near-infrared diffuse optical technique |
| Q91621787 | Detection of collagens by multispectral optoacoustic tomography as an imaging biomarker for Duchenne muscular dystrophy |
| Q38712657 | Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test |
| Q38965110 | Development of a patient-reported outcome measure for upper limb function in Duchenne muscular dystrophy: DMD Upper Limb PROM. |
| Q38125499 | Development of the Performance of the Upper Limb module for Duchenne muscular dystrophy |
| Q93172525 | Effectiveness of pharmacological treatments in Duchenne muscular dystrophy: a protocol for a systematic review and meta-analysis |
| Q92246076 | Electrical impedance myography for reducing sample size in Duchenne muscular dystrophy trials |
| Q41654042 | Electrical impedance myography in facioscapulohumeral muscular dystrophy |
| Q45855674 | Eteplirsen for the treatment of Duchenne muscular dystrophy |
| Q34171004 | Examination of effects of corticosteroids on skeletal muscles of boys with DMD using MRI and MRS. |
| Q24616493 | Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study |
| Q42117182 | Extensive Functional Evaluations to Monitor Aerobic Training in Becker Muscular Dystrophy: A Case Report |
| Q52506936 | Facioscapulohumeral Muscular Dystrophy. |
| Q27309179 | Gait characteristics in a canine model of X-linked myotubular myopathy |
| Q34625436 | Gene therapy for muscular dystrophy: moving the field forward |
| Q28554686 | Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy |
| Q24198280 | Interventions to prevent steroid-induced osteoporosis and osteoporotic fractures in Duchenne muscular dystrophy |
| Q39292845 | Investigating the quantitative fidelity of prospectively undersampled chemical shift imaging in muscular dystrophy with compressed sensing and parallel imaging reconstruction |
| Q37418497 | Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis |
| Q33435110 | Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study |
| Q94561306 | Longitudinal Study of Three microRNAs in Duchenne Muscular Dystrophy and Becker Muscular Dystrophy |
| Q38686541 | Longitudinal community walking activity in Duchenne muscular dystrophy |
| Q40316979 | Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy |
| Q90617376 | Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey |
| Q37019941 | Lower leg muscle involvement in Duchenne muscular dystrophy: an MR imaging and spectroscopy study |
| Q36279798 | MRI/MRS evaluation of a female carrier of Duchenne muscular dystrophy |
| Q37095860 | Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network |
| Q34341005 | One year outcome of boys with Duchenne muscular dystrophy using the Bayley-III scales of infant and toddler development |
| Q37867701 | Opportunities and challenges for the development of antisense treatment in neuromuscular disorders |
| Q34151082 | Percent-predicted 6-minute walk distance in duchenne muscular dystrophy to account for maturational influences. |
| Q36378973 | Periodic sound-based 6-minute walk test forpatients with Duchenne muscular dystrophy:a preliminary study |
| Q35069526 | Phase 2a study of ataluren-mediated dystrophin production in patients with nonsense mutation Duchenne muscular dystrophy |
| Q59876187 | Placebo-controlled Phase 2 Trial of Drisapersen for Duchenne Muscular Dystrophy |
| Q34630606 | Proof of concept of the ability of the kinect to quantify upper extremity function in dystrophinopathy |
| Q30527775 | Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures |
| Q44101750 | Quantitative muscle ultrasound and muscle force in healthy children: a 4-year follow-up study |
| Q36761839 | Recent developments in the treatment of Duchenne muscular dystrophy and spinal muscular atrophy |
| Q39000205 | Reference value for the 6-minute walk test in children and adolescents: a systematic review. |
| Q92189021 | Reliability and Validity of the 6-Minute Walk Test in Hypophosphatasia |
| Q35863802 | Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program |
| Q51298263 | Six-minute walk test in healthy children: is the leg length important? |
| Q38789047 | Six-minute walk test is reliable and valid in spinal muscular atrophy |
| Q31147166 | Six-minute walk test: reference values and prediction equation in healthy boys aged 5 to 12 years |
| Q51092139 | Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy. |
| Q35553292 | The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys |
| Q34836557 | The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year |
| Q30557216 | The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study |
| Q37298079 | The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study |
| Q47704395 | The Facioscapulohumeral Muscular Dystrophy Functional Composite Outcome Measure. |
| Q27021472 | The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? |
| Q53654199 | The clinical relevance of timed motor performance in children with Duchenne muscular dystrophy. |
| Q34103360 | The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used |
| Q33919009 | The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an |
| Q36351131 | The role of the neuromuscular medicine and physiatry specialists in the multidisciplinary management of neuromuscular disease |
| Q35959326 | Timed Rise from Floor as a Predictor of Disease Progression in Duchenne Muscular Dystrophy: An Observational Study |
| Q38841467 | Validity of the 6 minute walk test in facioscapulohumeral muscular dystrophy. |
| Q43449990 | Weakness and fatigue in diverse neuromuscular diseases |
| Q39376754 | Why short stature is beneficial in Duchenne muscular dystrophy |
| Q87092286 | [Functional and orthopaedic aspects of dystrophinopathies] |
Search more.